Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising demand for oral transmucosal drugs
3.2.1.2 Advancements in drug delivery technologies
3.2.1.3 Increasing prevalence of chronic diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements for drug approval and commercialization
3.2.2.2 High cost associated with research and development activities
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Technological landscape
3.9 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Tablets
5.3 Films
5.4 Liquid & spray
5.5 Other product types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Sublingual mucosa
6.3 Buccal mucosa
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Opioid dependence
7.3 Nausea and vomiting
7.4 Erectile dysfunction
7.5 Neurological disorders
7.6 Other indications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Aquestive Therapeutics, Inc.
10.2 C.L.Pharm Co., Ltd.
10.3 CURE Pharmaceutical
10.4 IntelGenx Corp
10.5 Jazz Pharmaceuticals
10.6 NAL Pharma
10.7 Novartis AG
10.8 Pfizer Inc.
10.9 Teva Pharmaceutical Industries Ltd.
10.10 ZIM Laboratories Limited.
